Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: FTSE (0.3%), DAX (0.4%), CAC (0.5%)

Jun 23 ,2025

  • Synopsis

    • European equity markets set to open broadly lower, extending last week's losses when the Stoxx Europe 600 ended down ~(1.5%). Asian equities mixed to mostly lower Monday as markets react to US strikes on Iran. Crude up ~1.5% but off initial highs. Markets awaiting potential Iranian response to US strikes on Fordow, Natanz and Isfahan nuclear facilities on Saturday. Lot of discussion about risk to crude disruptions through Strait of Hormuz after Iran's parliament voted symbolically in support of its closure. Meanwhile, Trump is reportedly floating Iran 'regime change' even as the true impact of US strikes is far from clear.

    • The week ahead sees NATO, EU-Canada and EU Leaders summits, German draft federal budget, Finland and Sweden holding annual political and societal forums, Eurozone, France, Germany, UK Jun flash manufacturing/services PMIs as well as earnings/updates from the likes of Babcock International Group (BAB.LN), H&M Hennes & Mauritz (HM.B.SS), Inchcape (INCH.LN), and Serco Group (SRP.LN).

    • In the UK, the Government unveils its new Industrial Strategy today. Electricity bills to be slashed for over 7,000 businesses.

    • In central banks today, Bundesbank's Theurer speech at 14:30CET at Univ. Bayreuth and Bundesbank's Nagel speech at 17:00 at Walter Eucken Institut. Czech central bank publishes Financial Stability Report and EU-Canada summit takes place. In Sweden, Almedalen Week (also known as Politician's Week in Almedalen and considered to be the most important forum in Swedish politics) (through Fri). Nordic co-operation hosting numerous events at Almedalen. EU's Kubilius participates in the round table discussion with new defence players and speech at discussion "European Defence Union - what is in the name?". Chancellor Merz speech at 14:20CET and EU's Šefčovič panellist on trade policy as part of the 'Day of Industry' event organised by Germany's BDI (through Tue) and the latter also speaks with Bundestag committee. POLITICO Pro Leaders Club - Danish Presidency Dinner at 20:00CET.

    • Quiet day for earnings/updates with Prosus (PRX.NA) scheduled to report FY earnings. Roche Holding (ROG.SW) holds Hematology pipeline 19:00CEST, while KBC (KBC.BB) is due to host ESG-CSR virtual event.

  • Politics/Macro/World News

    • Iran

      • Iran vows revenge on US, threatening to block vital shipping lane -- Times

      • Trump floats Iran 'regime change' even as the true impact of US strikes is far from clear-- CNN

    • ECB

      • Centeno (ECB): "Uncertainty over US tariffs weighs on growth, rates could fall further" -- La Stampa

    • UK

      • UK government set to unveil its bold new Industrial Strategy today - release --

      • UK government to invest more than £500mn in quantum computing -- FT

      • Energy prices cut for business as part of UK industrial strategy -- FT

    • Spain

      • Spain agrees with NATO to skip 5% defence spending target -- Reuters

  • Top company news

    • M&A

      • ENI.IM (Eni) -- Ares Alternative Credit to acquire 20% stake in Plenitude, controlled by Eni, for €2B ($2.30B)

      • FNAC.FP (Fnac Darty) -- expecting more M&A in Italy following UniEuro's acquisition -- CEO tells Corriere

      • CLA.FP (Claranova) -- agrees to sell its PlanetArt division to General Atlantic Credit and PlanetArt's management team

      • RGLS (Regulus Therapeutics) -- Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer

      • UCG.IM (UniCredit) -- completes internalisation of life bancassurance in Italy

      • RF.FP (Eurazeo) -- acquires majority stake in SMP Energies

      • GREEN.BB (Greenyard) -- Deprez group and Solum Partners launch, through Garden S.à r.l., voluntary and conditional takeover bid on Greenyard NV

      • EU sets a provisional deadline of 28-Jul to rule on Varo Energy's acquisition of Preem

    • Healthcare

      • LLY (Eli Lilly) -- Detailed results from ACHIEVE-1 trial of Eli Lilly's orforglipron presented at ADA Scientific Sessions, published in NEJM

      • AZN.LN (AstraZeneca) -- gives information on its seven abstracts to be presented at EAN

      • NOVO.B.DC (Novo Nordisk) -- presents results from STEP UP trial of Wegovy at ADA Scientific Sessions

      • NOVO.B.DC (Novo Nordisk) -- subcutaneous amycretin data presented at ADA Scientific Sessions, published in The Lancet

      • NOVO.B.DC (Novo Nordisk) -- REDEFINE 1 trial of Novo Nordisk's CagriSema meets co-primary endpoints; results published in NEJM

      • NOVO.B.DC (Novo Nordisk) -- presents results from phase 3B FRONTIER5 trial

      • ROG.SW (Roche Holding) -- Genentech presents results from Phase III SUNMO study for Lunsumio administered in combination with Polivy in people with relapsed or refractory large B-cell lymphoma

      • HLUN.B.DC (H. Lundbeck) -- SUNRISE trial of H. Lundbeck's Vyepti meets all primary, secondary endpoints

      • HLUN.B.DC (H. Lundbeck) -- RESOLUTION trial of H. Lundbeck's Vyepti meets all primary, secondary endpoints

      • 4519.JP (Chugai Pharmaceutical) -- presents first clinical data in people with hemophilia A from phase I/II study of NXT007 (11:34 JT)

      • IDIA.SW (Idorsia) -- reaches agreement with Simcere to update the terms of the licensing agreement for QUVIVIQ in China; to receive $50M (an additional $30M) approval milestone payment

      • MOLN.SW (Molecular Partners) -- and Orano Med to outline encouraging early preclinical proof-of-concept data for candidate MP0726 in presentation

    • Other

      • BP.LN (BP) -- Sam Laidlaw, Ken MacKenzie among candidates to replace Helge Lund as BP chair - Sky News

      • RR.LN (Rolls-Royce Holdings) -- Trent 1000 problems lurk for Rolls-Royce Holdings - Mail on Sunday

      • HOLN.SW (Holcim) -- completes spinoff of Amrize, for which trading will begin today, as expected

      • GLPG.NA (Galapagos) -- appoints Aaron Cox as new CFO

      • TIT.IM (Telecom Italia) -- announces Golden Power approval for the amendment of the corporate purpose of the bylaws received

      • TEP.FP (Teleperformance) -- announces intent to repurchase up to €100M of company shares intended for cancellation objective

      • GOGL.NO (Golden Ocean Group) -- and CMB TECH signed loan facilities of $2B to refinance outstanding debt in Golden Ocean

      • Estimated weekend box office revenues in US, Canada $125.3M, (18.5%) y/y - Box Office Mojo

  • Key rating changes

    • Upgrades

      • UCB.BB (UCB) -- to overweight from equal-weight at Morgan Stanley

    • Downgrades

      • DEME.BB (DEME Group) -- to neutral from outperform at Oddo

      • ERIC.B.SS (Ericsson) -- to hold from buy at Handelsbanken

      • MUV2.GR (Munich Re) -- to underweight from equal-weight at Morgan Stanley

      • SREN.SW (Swiss Re) -- to underweight from equal-weight at Morgan Stanley

      • UPR.LN (Uniphar) -- to hold from buy at Deutsche Numis

    • Initiations

      • GRE.SM (Grenergy Renovables) -- outperform at Mediobanca

      • BOOT.LN (Henry Boot) -- buy at Jefferies

      • HWG.lN (Harworth Group) -- buy at Jefferies

      • PFSE.GR (PFISTERER Holding) -- neutral at Oddo

  • Data

    • Nikkei (0.17%) to 38338.54

    • Hang Seng +0.28% to 23597.50

    • Shanghai Composite +0.28% to 3369.30

    • S&P futures (9.5) vs prior close of 6018.0

    • €-$ +0.0040 or +0.35% to 1.1513

    • $-¥ +0.55 or +0.37% to 147.21

    • €-¥ +1.22 or +0.73% to 169.47

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE